Jazz Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.About JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
CEORenée D. Galá
CEORenée D. Galá
Employees2,800
Employees2,800
HeadquartersDublin, Dublin
HeadquartersDublin, Dublin
Founded2005
Founded2005
Employees2,800
Employees2,800
JAZZ Key Statistics
Market cap8.36B
Market cap8.36B
Price-Earnings ratio-20.40
Price-Earnings ratio-20.40
Dividend yield—
Dividend yield—
Average volume641.52K
Average volume641.52K
High today$138.36
High today$138.36
Low today$136.67
Low today$136.67
Open price$137.23
Open price$137.23
Volume263.57K
Volume263.57K
52 Week high$148.06
52 Week high$148.06
52 Week low$95.49
52 Week low$95.49
JAZZ News
Simply Wall St 1d
Are Jazz Pharmaceuticals Shares Still Attractive After a 25% Climb and New Pipeline Developments?Curious if Jazz Pharmaceuticals is a hidden value in the biotech sector or if its recent run means the best opportunities have already passed? You are not alone...
Simply Wall St 3d
How Investors May Respond To Jazz Pharmaceuticals Settling Global LUMRYZ Patent Dispute with AvadelIn October 2025, Avadel Pharmaceuticals announced a global settlement with Jazz Pharmaceuticals, resolving all ongoing litigation regarding LUMRYZ and related s...
TipRanks 6d
Jazz Pharmaceuticals Appoints Dr. Ted Love to BoardElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
95%
of 20 ratingsBuy
95%
Hold
5%
Sell
0%
People also own
Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.